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Hemochromatosis C282Y gene mutation increases
the risk of venous leg ulceration
Paolo Zamboni, MD, Silvia Tognazzo, BS, Marcello Izzo, MD, Francesca Pancaldi, MD,
Gian L. Scapoli, MD, Alberto Liboni, MD, and Donato Gemmati, BS Ferrara, Italy
Objective: Chronic venous disease (CVD) is the most common vascular disorder, progressing in approximately 10% of
cases toward chronic venous leg ulceration, whereas the hemochromatosis gene (HFE) C282Y mutation is the most
common recognized genetic defect in iron metabolism. Because CVD leads to local iron overload in the affected legs, we
investigated whether two common HFE mutations could increase the risk of chronic venous leg ulceration.
Methods: This was a case-control study at the Vascular Diseases Center, University of Ferrara, Italy. From a cohort of 980
consecutive patients affected by severe CVD (CEAP clinical classes C4 to C6) we selected 238 cases with the exclusion of
any other comorbidity factor potentially involved in wound etiology (group A). They were subdivided into group B,
including 137 patients with ulcer (classes C5 and C6: 98 primary and 39 postthrombotic cases), and group C, including
101 cases with no skin lesions (class C4). They were completely matched for sex, age, and geographic origin with 280
healthy controls (group D). A total of 518 subjects were polymerase chain reaction genotyped for HFE mutations
(C282Y and H63D). We assessed the risk of ulceration by comparing the prevalence of ulcer in homogenous cases with
and without the HFE variants. Other main outcome measures were the sensitivity, specificity, and predictive values of the
genetic test in CVD cases.
Results: C282Y mutation significantly increases the risk of ulcer in primary CVD by almost seven times (odds ratio, 6.69;
95% confidence interval, 1.45-30.8; P  .01). Application of the HFE test in primary CVD demonstrated increased
specificity and positive predictive values (98% and 86%, respectively), with negligible sensitivity and negative predictive
values.
Conclusions: The overlap of primary CVD and the C282Y mutation consistently increases the risk of developing venous
leg ulceration. These data, which have been confirmed in other clinical settings, suggest new strategies for preventing and
treating primary CVD.
Clinical Relevance: The number of patients affected by primary CVD is so great that the vast majority of ulcers are also
related to this common problem. On the other hand, there is not a reliable way for identifying in advance, from the broad
base of primary CVD patients (20–40% of the general population), the high risk minority (10% of primary CVD cases)
who will develop a venous ulcer. In such cases, a simple C282Y blood genetic test demonstrated an elevated specificity in
predicting ulcer development (98%, CI 95%, 92.8–99.7). The genetic test could be applied starting from the C2 class,
varicose veins, the most common situation observed in clinical practice. In perspective, the presence of the C282Y
mutation would strengthen the indications and priorities for surgical correction of superficial venous insufficiency.
(J Vasc Surg 2005;42:309-14.)C282Y and H63D mutations of the hemochromatosis
(HFE) gene are the most common genetic defects in he-
reditary hemochromatosis gene (HH) in Caucasian popu-
lations, and the associated risk is increased by the homozy-
gous condition for C282Y or by coinheritance of both
variants. It was recently discovered that these genetic de-
fects present lower penetration than previously thought
and cannot be advocated alone for the development ofHH.
Therefore, to develop iron overload pathologies, other
inherited or acquired conditions are necessary, such as
environmental factors, concomitant diseases, or both.1,2
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variants are generally considered asymptomatic carriers.
An even more common condition that affects the general
population is chronic venous disease (CVD). Affecting
20% to 50% of the Caucasian population, CVD is the
most widespread vascular pathology. In most cases, it is a
minimally disabling disease, but in approximately 10%
of cases it progresses toward chronic venous leg ulcer-
ation, the overall prevalence of which is 1% to 2% in the
United States and Europe, with an estimated health care
expenditure of $1 billion per year in the United States
alone.3,4
Impairment of venous hemodynamics is an essential
but insufficient factor in explaining the progression of the
disease to the point of skin lesions. One of the critical
objectives for physicians involved in evaluating and treating
CVD is to identify a prognostic factor for ulcer onset.
Clinical and hemodynamic parameters, including duplex
scanning and plethysmographic investigations, fail to pre-
dict ulcer appearances and are insufficient for categorizing
patients by the clinical severity of the disease.5-8 For such
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during the past 20 years in an attempt to understand the
etiology of venous ulceration, but none of them completely
explains the entire process.9-11
Finally, numerous authors have demonstrated that a
local iron overload exists in CVD-affected limbs.12-16 This
is due to the diapedesis of erythrocytes that enter the
interstice through fenestrations in the capillaries under
conditions of chronic venous stasis.17 The heme catabolism
at the interstitial level causes hemosiderin deposits at both
the phagocyte and extracellular levels (Fig 1).
Local iron overload is not negligible, and hemosiderin
granules have been found even in the urine of patients
affected by CVD.15 Several authors have hypothesized that
this iron could be released to generate free radicals because
of excessive oxidative stress, to activate a proteolytic hyper-
activity on the part of metalloproteinases, or to downregu-
late tissue inhibitors of metalloproteinases.14,16-20 It re-
mains to be explained why iron overload, always visible to
the naked eye in the hyperpigmentation of clinical class C4,
causes lesions in some individuals, whereas in others it does
not. It has recently been demonstrated that patients with
ulcer have a higher concentration of iron and rate of trans-
ferrin saturation in the serum from the affected leg than do
C4 patients. It seems that patients with ulcer lose the ability
to counteract the iron export from inside the phagocytes,
and it has been hypothesized that this inability could be
genetically determined.20 In an attempt to understand this
patient-to-patient difference, we investigated whether, in
the population affected by CVD, the two principal HFE
mutations could play a determining role in the formation of
Fig 1. The iron from senescent erythrocytes migrated in
up by macrophages and stored in ferritin-like structures.
C282Y mutation have less stability than wild types, a
developing ulcers in course of chronic venous dise
Hemochromatosis.venous ulcers.METHODS
Selection of cases and controls. We studied 238
patients affected by severe CVD (CEAP clinical classes C4
to C6) from different areas of Italy, selected from an initial
cohort of 980 patients who were referred to our Vascular
Diseases Center. For purposes of patient selection, these
subjects underwent clinical and duplex scanning examina-
tions. This investigation, conducted in accordance with
consensus statement criteria and a method previously de-
scribed,5-8 allowed us to separate primary from postthrom-
botic cases and to identify patients affected by peripheral
arterial disease.
For patient selection, we strictly applied the following
exclusion criteria to exclude any other comorbidity factor
potentially involved in wound etiology:
1. Diabetes
2. Peripheral arterial disease or ankle-brachial index less
than 0.9
3. Hemolytic anemia, iron-deficiency anemia, or malnutri-
tion
4. Inability to walk
5. Severe cardiac, hepatic, renal, or pulmonary insuffi-
ciency
6. Chronic administration of cortisones for chronic inflam-
matory disease or autoimmune disease
Applying these exclusion criteria, we selected 238 cases,
which constituted group A. These patients were subse-
quently divided into 2 groups: group B, 137 subjects with
ulcers in the lower limbs of certain venous origin (clinical
classes C5 and C6), and group C, 101 subjects who had
e matrix in the condition of chronic venous stasis is taken
intracellular iron deposits of macrophages carrying the
e mutation is significantly associated with the risk of
Perls staining; original magnification, 400). HFE,to th
Such
nd th
ase (never had skin lesions, of which 98 had primary and 3 had
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comparable for distribution of sex, age, area of geographic
origin, and presence of primary or postthrombotic CVD in
the ulcer group, as reported in Table I.
We also considered the area of birth of both subjects
and their parents because in Italy the frequency of the two
principal HFE mutations is heterogeneous: whereas in the
north it is similar to that of Central Europe, in the south it
is much lower.2,20-22 The boundary line between Northern
and Southern Italy is usually considered to be the Apenni-
nes mountain chain, and we applied this criterion to our
patient population (Table I). Finally, we subdivided the
ulcer group B, in accordance with the pathogenesis and
pathophysiology, into primary (subgroup F) and post-
thrombotic (subgroup E) ulcers.
The controls (group D) were 280 healthy subjects
selected from among blood donors who were matched for
sex, age, and geographic origin with the patients described
previously (Table I). The total of 518 subjects (137 affected
by venous ulcers, 101 affected by severe CVD, and 280
normal controls) underwent polymerase chain reaction
genotyping for H63D and C282YHFE gene mutations on
chromosome 6.
DNA analysis. Genomic DNA was isolated from pe-
ripheral blood by using standard proteinase K treatment,
followed by phenol-chloroform extraction and ethanol pre-
cipitation. Samples were polymerase chain reaction geno-
typed for C282Y and H63D HFE variants according to
previous reports.21 Genotypes were confirmed by regeno-
typing a random selection of samples (cases and controls)
for each polymorphism investigated. There were no dis-
crepancies between genotypes determined in duplicate.
Statistical analysis. Statistical differences between
case and control populations were determined by using the
2 test. Where appropriate, the Yates correction or Fisher
exact test was applied. P values .05 were considered
statistically significant. Odds ratios (ORs) and 95% confi-
dence intervals (CIs) were used to estimate the risk of
developing venous ulcers. Adjusted ORs for single or com-
bined comparisons were calculated by means of logistic
regression models that controlled for sex, age, geographic
origin, and the H63D polymorphism. Risk assessment for
Table I. Patient population demographics
Variable
Group A, all
CVD patients
(n  238)
Group B, venous
ulcer patients
(n  137)
Grou
CVD;
(n
Age (y)
Mean  SD 61.03  12.95 63.7  13.18 58.0
Median (range) 61 (27-85) 63 (34-85) 58
Sex, M/F 31.9/68.1 35.8/64.2 26
(%; n) (76/162 ) (49/88) (2
North/south 67.2/32.8 69.3/30.7 64
(%; n) (160/78 ) (95/42) (6
No significant differences were observed in the subgroups considered amon
CVD, Chronic venous disease.ulceration was performed by comparing the prevalence ofulcer in cases with and without the HFE variants. In addi-
tion, we assessed the sensitivity, specificity, and positive and
negative predictive values in CVD cases of the genetic test
under study. The expected frequency of control genotypes
was checked by using the Hardy-Weinberg equilibrium
test. All analyses were performed by Systat version 5.0
(Systat Inc, Evanston, Ill) and the SPSS statistical package
(version 10.1; SPSS Inc, Chicago, Ill).
RESULTS
HFE H63D and C282Y distribution in cases and
controls. Fig 2 shows the allele and genotype distributions
of the H63D and C282Y variants in the entire cohort of
238 CVD cases, in the subset groups, and in the healthy
controls. In our ulcer cases (group B), the prevalence of the
C282Y polymorphic allele was significantly increased com-
pared with healthy controls (5.1% vs 2.1%; P  .035).
When we compared group B with C4 patients without skin
lesions (group C), the prevalence demonstrated a similar,
although not significant, appreciable difference (5.1% vs
1.5%; P .063). It is interesting to note that the prevalence
of the C282Y polymorphic allele found in C4 cases of
group C (1.5%) was less than that in healthy controls
(2.1%); however, such a difference is nonsignificant (P 
.778), and thus it cannot be considered a protective mech-
anism. Moreover, when patients affected by primary ulcer
(subgroup F) were computed vs healthy controls or C4
cases, the difference in prevalence of such a variant dramat-
ically increased (6.6% vs 2.1%, P .005; and 6.6% vs 1.5%,
P  .018, respectively). Finally, further analysis of preva-
lence by comparing primary ulcer vs primary C4 cases
showed a highly significant difference (6.6% vs 1.02%; P 
.008).
Although the prevalence of double carriers of the vari-
ants under study (H63D/C282Y) found in the primary
CVD group was greater than among healthy controls
(3.06% vs 1.07%, respectively), it was not significantly
higher (P  .357). Very interestingly, neither in the case
group (group C) without lesions nor in the subgroup with
postthrombotic ulcers were double carriers identified. Fi-
nally, the frequencies of the twomutations registered in the
healthy control population seemed very similar to those
severe
r ulcer
1)
Subgroup F,
primary ulcer
(n  98)
Subgroup E,
postthrombotic ulcer
(n  39)
Group D,
healthy controls
(n  280)
3.12 63.0  12.72 65.0  14.12 61.5  13.50
84) 62.5 (34-84) 66 (41-85) 61 (27-85)
3.3 33.7/66.3 41/59 33.2/66.7
4) (33/65) (16/23) (93/187 )
5.6 71.4/28.6 64.1/35.9 66.4/33.6
6) (70/28) (25/14) (186/94 )
comparisons of computed parameters.p C,
neve
 10
4  1
(27-
.7/7
7/7
.4/3
5/3previously reported for the Italian population.21-23
 wil
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predictivity. Table II shows the assessment of risk of
ulceration by comparing the prevalence of ulcer in our
homogeneous CVD cases carrying or not carrying the
C282Y variant. The calculated ulcer risk in the entire
cohort of CVD, although certainly appreciable, did not
yield statistical significance (OR, 3.07; 95% CI, 0.83-
11.32; P  .085). In contrast, in primary CVD, the risk
increased by almost seven times when the C282Y variant
was present (OR, 6.69; 95% CI, 1.46-30.8; P  .01).
Consequently, in subjects affected by postthrombotic
ulcer (subgroup E), the C282Y mutation did not seem to
Fig 2. Allele and genotype distributions of the H63D a
disease (CVD) cases, in the subset groups, and in the hea
are referred to polymorphic allele frequencies. *Significan
  heterozygotes,   wild types.
Table II. Assessment of ulceration risk in CVD cases
Severe CVD; entire group (n  238)
HFE C282Y
Ulcer
(n  137)
No ulcer
(n  101)
CC (n  222) 124 (55.8%) 98 (44.2%)
CY  YY (n  16) 13 (81.3%) 3 (18.7%)
OR (95% CI; P) 3.42 (0.95-12.35; .085)
CVD, Chronic venous disease; OR, odds ratio; CI, confidence interval. CCbe associated with a significant risk. It is noteworthy thatmore than 85% of C282Y carriers in primary cases devel-
oped an ulcer, whereas ulcer occurred in only 47% (P 
.01) of the wild types (Table II). Furthermore, we did
not find any increased risk in any group regarding H63D
mutation.
The specificity of the genetic test in predicting ulcer
development in primary CVD cases was 98% (95% CI,
92.8%-99.7%), with a corresponding positive predictive
value of 86% (95% CI, 57.1%-98.2%). On the contrary,
assessment of sensitivity and negative predictive values was
certainly less interesting for future clinical application (12%:
95% CI, 6.0%-20%; and 53%: 95% CI, 45.1%-98.2%, re-
82Y variants in the entire cohort of 238 chronic venous
ontrols. Odds ratios (ORs) and 95% confidence intervals
lts. Post-Thromb, Postthrombotic, homozygotes,
Primary CVD (n  196)
HFE C282Y
Ulcer
(n  98)
No ulcer
(n  98)
CC (n  182) 86 (47.2%) 96 (52.8%)
CY  YY (n  14) 12 (85.7%) 2 (14.3%)
OR (95% CI; P) 6.69 (1.45-30.8; .01)
d types, CY  heterozygotes, YY  homozygotes.nd C2
lthy c
t resuspectively).
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The main finding of this study is that, in patients with
primary CVD (the most common situation observed in
clinical practice), the presence of theHFEC282Y polymor-
phic allele significantly increases the risk of developing an
ulcer (Fig 2 and Table II). The consequent increased risk
recorded in our population of patients affected by primary
CVDwasmore significant than that for any other predictive
parameter for venous ulcer reported to date.5,6
In addition, a positive test in case of primary CVD was
highly predictive of ulcer development. In clinical practice,
this finding suggests new prospects for the prevention and
treatment of primary CVD. The proportion of CVD pa-
tients affected by primary superficial venous disease is so
great that the vast majority of ulcers must also be related to
this common problem. It has been demonstrated in 85% of
ulcer cases that the disorder was referred to primary CVD,
but with a combination of superficial and deep reflux in 32%
and with a pattern of reflux confined to the superficial
venous system in 53%. Isolated deep reflux, mainly in
postthrombotic limbs, was found in only 15% of total ulcer
cases, and these data were confirmed in other studies.24-26
Thus, our data are potentially applicable to the broad
base of primary CVD patients because, among the many
who have varicose veins (class C2), only 10% will develop a
venous ulcer. This high-risk minority could be identified in
advance by means of a simple blood test that would act as a
genetic screening device. Then such preventive measures as
elastic stockings, superficial venous surgery, and avoidance
of iron-rich foods and dietary supplements could be used in
a targeted program of potentially great effectiveness. Thus,
primary CVD could be treated more appropriately before
any lesions develop in patients with particular genetic hap-
lotypes. Vascular surgery practice could be strongly influ-
enced by the results of the HFE genetic test; the C282Y
mutation would strengthen the indications and priorities
for surgical correction of superficial venous insufficiency.
It is known that circulating neutrophils are first trapped
in the venous microcirculation.10 Red blood cell degrada-
tion products and interstitial protein extravasation are po-
tent chemoattractants and presumably represent the initial
underlying chronic inflammatory signal responsible for
macrophage recruitment from trapped monocytes. Pappas
et al27 established, by means of morphometric assessment,
that macrophages are the predominant cells observed in
patients with CVD and severe dermal skin changes: this
clearly indicates the central role of macrophages in the
chronic inflammatory process of the ulcer bed.
Our results suggest a less favorable management of the
iron deposits in the legs of C282Y patients with respect to
wild types. It is known that the iron from red blood cells
sequestered in the extracellular matrix is bound to ferritin
and then to hemosiderin or taken up by phagocytes; inside
these cells, the iron is arranged in ferritin-like structures,
where it can be stored for years (Fig 1).13-17,23 Such
defensive mechanisms should avoid the generation of free
iron and, consequently, of highly aggressive free radicals.Even though iron metabolism is still poorly under-
stood, some evidence in the literature suggests that intra-
cellular iron deposits of macrophages carrying the C282Y
mutation have less stability than the wild types. The mu-
tated macrophages lose the ability to counteract the in-
creased iron export from inside the cell.23 In addition, it has
been demonstrated that the mutated phagocytes, after hav-
ing taken up the senescent red blood cells, release twice the
amount of non–transferrin-binding iron and at a lower
molecular weight with respect to the wild types.28 These
already-known effects of the C282Y mutation on human
macrophages, if speculatively related to our findings, can
lead us to assume that the mutated macrophages increase
the possibility of generating free iron and free radicals,
possibly leading to matrix breakdown and skin le-
sions.14,16,18,19,29
Thus, it seems that mutated macrophages potentially
release more iron from inside the cell and that this effect is
related to ulcer appearance. This finding is confirmed by
previous studies in which a significantly higher serum iron
and percentage of transferrin saturation were assessed in the
legs of ulcer patients as compared with either the arm serum
of the same subjects or with controls.12,20 This gene varia-
tion could offer a plausible explanation for such a phenom-
enon.
In our study, the H63D mutation by itself did not
prove to play the same role as the C282Y mutation in
facilitating the occurrence of ulcerous lesions. However,
H63D/C282Y compound carriers are overrepresented, al-
though not significantly, in our primary chronic venous leg
ulceration cases. We believe that this lack of significance is
due to the relatively small number of compound carriers
found overall. However, such a finding undoubtedly as-
cribes an appreciable role in ulcer pathogenesis to the
coinheritance of the two defects, as previously demon-
strated for HH.1,2 This idea is strengthened by the fact that
no compound heterozygotes were found in the postthrom-
botic and C4 groups.
Similarly, neither the C282Y nor the H63D mutation
seems to be significantly associated with the appearance of
ulcers in patients affected by CVD secondary to postthrom-
botic syndrome. This lack of association could be attributed
to the well-known greater hemodynamic impairment in
postthrombotic as compared with superficial and primary
cases.5 Finally, the slight underrepresentation of the C282Y
mutation in both postthrombotic and C4 cases was proba-
bly due to a chance rather than a protective effect.
It will be interesting to determine whether our findings
observed in the Italian population can be observed in other
countries. In Italy and Greece, the C282Y mutation is
much less frequent than in Northern Europe. In a review
analyzing nine reports from Italy, allele frequencies for the
C282Y were calculated to average 1.7%, with an inverted
gradient from north to south (range, 4.2%-0.5%); the same
analysis showed a decreased frequency in Europe from the
north to the Mediterranean basin: Ireland, 9.7%; United
Kingdom, 8.2%; Norway, 6.6%; Brittany and Northern
France, 7.7%; Southern France, 2.6%; Germany, 4.2%; and
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venous ulcers also have a significant epidemiologic effect.
In Italy, venous ulcers are correspondingly less frequent
than in Northern Europe, although CVD has the same
prevalence.2,4,20-22,25,26,30 It could be speculated that the
greater frequency of venous ulcers in Northern Europe is
related to the greater frequency of HFE mutations in these
countries. We speculate that the C282Y variant could play
a pivotal role in ulcer risk even in areas of the United States
that have high prevalences of Northern European descent,
such as New England and the North Central states.
In conclusion, the overlap of primary CVD and the
C282Y mutations consistently increases the risk of devel-
oping venous leg ulceration. Because this finding suggests
new prospects for the prevention and treatment of primary
CVD, we believe that further research in other clinical
settings, including an international multicenter study, is
warranted to determine whether similar results can be
obtained and whether their clinical implications can be
confirmed.
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